

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/045,180
Filing Date	October 18, 2001
First Named Inventor	Lydie Bougueleret
Art Unit	1645 1644
Examiner Name	Unassigned VanderVest
Attorney Docket Number	GEN-100D1

Sheet

1

of

3

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
R N	U1	US- 5,242,902	09-07-1993	Murphy et al.	All
	U2	US- 5,841,497	08-24-1997	Bevins et al.	All
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
R N	F1	WO 89/11291	11-30-1989	Invitron Corp.	All	
	F2	WO 94/21672	09-28-1994	Regents of U. of Calif.	All	
	F3	WO 95/32287	11-30-1995	Magalnin Pharmaceuticals	All	
	F4					
	F5					
	F6					
	F7					
	F8					
	F9					
	F10					

Examiner Signature		Date Considered	12/16/05
-----------------------	--	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449B/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/045,180
Filing Date	October 18, 2001
First Named Inventor	Lydie Bougueleret
Group Art Unit	1645-1644
Examiner Name	Unassigned VanderVeg
Attorney Docket Number	GEN-100D1

Sheet 2 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
A	R1	BEVINS, et al. [1996] "Human Enteric Defensin Genes: Chromosomal Map Position and a Model for Possible Evolutionary Relationship", <i>Genomics</i> , 31:95-106	
	R2	GANZ et al. [1994] "Defensins", <i>Current Opinion in Immunology</i> , 6:584-589	
	R3	GANZ et al. [1995] "Defensins", <i>Pharmac Ther.</i> , 66:191-205	
	R4	HUGHES, A. [1999] "Evolutionary Diversification of the Mammalian Defensins", <i>CMLS, Cell. Mol. Life Sci.</i> 56:94-103	
	R5	HUGHES, A. et al. [1997] "Coordinated Amino Acid Changes in the Evolution of Mammalian Defensins", <i>J. Mol. Evol.</i> 44:675-82	
	R6	KAGAN et al. [1994] "Defensins: a Family of Antimicrobial and Cytotoxic Peptides", <i>Toxicology</i> , 87:131-149	
	R7	LEHRER et al. [1992] "Defensins: Endogenous Antibiotic Peptides from Human Leukocytes", <i>Ciba Foundation Symposium</i> 171:276-293	
	R8	LERNER R. [1982] "Tapping the Immunological Repertoire to Produce Antibodies of Predetermined Specificity", <i>Nature</i> 299:592-96	
	R9	MALLOW et al. [1996] "Human Enteric Defensins", <i>The Journal of Biological Chemistry</i> 271:4038-4045	
	R10	MARTIN et al. [1995] "Defensins and Other Endogenous Peptide Antibiotics of Vertebrates", <i>Journal of Leukocyte Biology</i> 58:128-136	
	R11	RAJ, P. [2000] "Large-scale Synthesis and Functional Elements for the Antimicrobial Activity of Defensins", <i>Biochem. J.</i> 347:633-41	
	R12	SPARKES et al. [1989] "Assignment of Defensin Gene(s) to Human Chromosome 8p23", <i>Genomics</i> 5:240-244	
	R13	WHITE et al. [1995] "Structure, Function, and Membrane Integration of Defensins", <i>Current Opinion in Structural Biology</i> 5:521-527	



Examiner Signature		Date Considered	12/16/05
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

+

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/045,180		
		Filing Date	October 18, 2001		
		First Named Inventor	Lydie Bougueleret		
		Group Art Unit	1645 1644		
		Examiner Name	Unassigned Vanderkast		
Sheet	3	of	3	Attorney Docket Number	GEN-100D1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
R	R14	WILDE et al. [1989] "Purification and Characterization of Human Neutrophil Peptide 4, a Novel Member of the Defensin Family", <i>Journal of Biological Chemistry</i> 264 (19):11200-11203	
	R15		
	R16		
	R17		
	R18		
	R19		
	R20		
	R21		
	R22		
	R23		
	R24		
	R25		
	R26		

Examiner Signature		Date Considered	12/16/05
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+